证券代码：870199 证券简称：倍益康 公告编号：2023-065 四川千里倍益康医疗科技股份有限公司 关于取得医疗器械注册证的公告 序号 产品名称 证书编号 注册类别 证书有效期 适用范围 1 便携式制 氧机 川械注准 20232080300 II 类 2023 年 10 月 7 日至 2028 年 10 月 6 日 产品以空气为原料， 利用分子筛变压吸附 工艺生产富氧空气， 氧浓度范围为≥90% (V/V)，供氧疗或缓解 因缺氧导致的不适。 一、 注册证具体情况 三、 风险提示 上述注册证书涉及的产品实际销售情况取决于未来市场推广效果，目前尚无 法预测该产品对公司未来营业收入的影响，敬请投资者注意投资风险。 特此公告。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 四川千里倍益康医疗科技股份有限公司（以下简称"公司"）近期取得 1 项四川省药品监督管理局颁发的《医疗器械注册证》，具体情况如下： 二、 对公司的影响 上述医疗器械注册证书的取得，体现了公司在医疗器械方面的技术创新以及 自主研发能力， ...

证券代码：870199 证券简称：倍益康 公告编号：2023-064 四川千里倍益康医疗科技股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 四川千里倍益康医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日接待了 1 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2023 年 8 月 28 日 调研形式：网络调研 调研机构：开源证券 上市公司接待人员：董事长兼总经理张文先生、董事兼副总经理张莉评女士、 董事王露女士、证券事务代表奚旺先生 二、 调研的主要问题及公司回复概要 问题 1：公司大部分收入来自出口，渠道受到影响主要是哪些方面？ 回答：目前来看，筋膜枪市场整体还处于秩序建立阶段，市场上产品用料 大致分为两类，一是使用有刷电机，另外是使用无刷电机。其中无刷电机使用 寿命可达上万小时，而有刷电机寿命不足 1000 小时，且力度较难达到最佳需 求。两类材料成本差异极大，消费者较难分辨。从海外市场来看，目前亚马逊 上绝 ...

证券代码：870199 证券简称：倍益康 公告编号：2023-063 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 四川千里倍益康医疗科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司于 2022 年 11 月 3 日收到中国证券监督管理委员会下发的《关于同意 四川千里倍益康医疗科技股份有限公司向不特定合格投资者公开发行股票注 册的批复》（证监许可〔2022〕2681 号），同意公司向不特定合格投资者公开发 行股票的注册申请。公司本次发行的发行价格为 31.80 元/股，发行股数为 11,300,000 股，实际募集资金总额为 359,340,000.00 元，扣除支付的承销保荐 费用后实际转入募集资金专户的金额为 338,585,283.02 元。截至 2022 年 11 月 24 日，上述募集资金已到账，并由信永中和会计师事务所（特殊普通合伙）进 行审验，出具了 XYZH/2022CDAA1B0023 号验资报 ...

证券代码：870199 证券简称：倍益康 公告编号：2023-060 四川千里倍益康医疗科技股份有限公司 独立董事关于第三届董事会第十三次会议相关议案事项的 独董意见 因此，我们一致同意此项议案，该议案无需提交股东大会审议。 一、针对《关于公司<2023 年半年度报告及其摘要>的议案》的独立意见 经审阅，我们认为公司《2023 年半年度报告》及《2023 年半年度报告摘要》 的编制和审议程序符合法律法规及《公司章程》等规定，报告的内容和格式符合 北京证券交易所发布的相关规则的规定，报告所包含的信息能够从各个方面真实 的反映出公司本年度的经营管理和财务状况等事项。公司董事会对该议案的审议 及表决程序符合国家有关法律法规、《公司章程》及《董事会议事规则》的规定， 程序合法有效。 因此，我们一致同意此项议案，该议案无需提交股东大会审议。 二、针对《关于<2023 年半年度募集资金存放与实际使用情况的专项报告> 的议案》的独立意见 经审阅，我们认为《2023 年半年度募集资金存放与实际使用情况的专项报 1 告》真实的反映了公司募集资金的使用情况，有利于投资者对公司的募集资金使 用情况进行深入的了解。公司董事会对该议案 ...

四川千里倍益康医疗科技股份有限公司 证券代码：870199 证券简称：倍益康 公告编号：2023-058 1.会议召开时间：2023 年 8 月 23 日 2.会议召开地点：公司会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2023 年 8 月 13 日以书面方式发出 5.会议主持人：董事长张文 第三届董事会第十三次会议决议公告 6.会议列席人员：全体监事和高级管理人员 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 7.召开情况合法、合规、合章程性说明： 一、会议召开和出席情况 （一）会议召开情况 本次会议的召集、召开、议案审议程序等方面符合《公司法》等法律、行 政法规、部门规章、规范性文件和《公司章程》《董事会议事规则》的规定。 （二）会议出席情况 会议应出席董事 8 人，出席和授权出席董事 8 人。 董事聂采现、王伦刚、易阳因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于公司<2023 年半年度报告及其摘要>的议案》 1.议案内容： 由张文董事长从 ...

证券代码：870199 证券简称：倍益康 公告编号：2023-059 四川千里倍益康医疗科技股份有限公司 第三届监事会第十一次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 8 月 23 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 5.会议主持人：监事会主席王刚 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、议案审议程序等方面符合《公司法》等法律、行 政法规、部门规章、规范性文件和《公司章程》《监事会议事规则》的规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司<2023 年半年度报告及其摘要>的议案》 1.议案内容： 由监事会主席王刚从基本情况、财务情况、股东情况、董监高和核心员工 情况、公司治理及内部控制情况和公司持续经营等方面介绍《2023 年半年度报 告》及《2023 年半年度报告摘要》所涉内容。 具体内 ...

Financial Performance - The company reported a revenue of ¥165,677,074.86 for the current period, a decrease of 17.87% compared to ¥201,722,339.66 in the same period last year[20]. - The net profit attributable to shareholders was ¥22,027,933.91, down 49.54% from ¥43,657,234.79 in the previous year[20]. - The gross profit margin decreased to 36.90% from 40.95% year-on-year[20]. - The weighted average return on equity based on net profit attributable to shareholders was 4.22%, down from 28.67% in the previous year[20]. - Revenue declined by 17.87% to ¥165,677,074.86, compared to a growth of 63.81% in the same period last year[23]. - Net profit fell by 49.84% to ¥22,027,933.91, down from a growth of 44.06% in the previous year[23]. - The company achieved a non-recurring profit of ¥5,273,649.44 after tax, with total non-recurring gains amounting to ¥6,197,150.80[24]. - The company reported a net cash flow from operating activities of ¥7,743,683, a decrease of 65.16% compared to ¥22,229,341 in the same period last year[22]. - Other business income increased by 167.76% to CNY 3.37 million, compared to CNY 1.26 million in the previous year[40]. - The company’s overseas revenue decreased by 43.08% to CNY 49.16 million, impacted by weak global economic recovery and reduced consumer willingness[44]. Asset Management - The total assets at the end of the current period were ¥590,557,409.71, a decrease of 3.48% from ¥611,828,316.57 at the end of the previous year[21]. - Total assets decreased by 3.48%, down from a growth rate of 20.78% in the previous year[23]. - Cash and cash equivalents increased by 44.35% to ¥105,950,506.08, compared to ¥73,395,855 in the previous year[31]. - Accounts receivable at the end of the reporting period amounted to CNY 42.72 million, an increase of CNY 10.85 million, or 34.04%, primarily due to sales payments not yet settled within the credit period[32]. - Current assets totaled ¥494,949,499.88 as of June 30, 2023, down from ¥552,691,028.72 on December 31, 2022, representing a decrease of approximately 10.4%[92]. - Total liabilities decreased to ¥87,854,977.75 from ¥93,872,251.73, a reduction of about 6.8%[94]. - Total equity attributable to shareholders decreased to ¥501,582,490.39 from ¥517,956,064.84, a decline of approximately 3.2%[94]. - Non-current assets increased to ¥95,607,909.83 from ¥59,137,287.85, representing an increase of approximately 61.5%[93]. Strategic Initiatives - The company established a new subsidiary, Dongguan Beilukang Electronic Technology Co., Ltd., on April 6, 2023, to enhance its upstream supply chain[2]. - The company plans to implement a dual-brand strategy combining ODM and its own brand "beoka" to enhance market presence and customer engagement[28]. - The company is focused on enhancing its market position and competitive strength through strategic investments and acquisitions[52]. - The company plans to optimize online brand promotion strategies and explore new sales channels to mitigate risks[54]. - The company has initiated a share repurchase plan to enhance shareholder value and support employee stock ownership plans, reflecting confidence in future growth[60]. - The company plans to enhance product promotion and development to align with consumer trends and preferences, aiming to expand market share[56]. - The company anticipates continued growth in the rehabilitation and therapy equipment manufacturing industry, driven by advancements in artificial intelligence and personalized rehabilitation needs[29]. Research and Development - The company holds a total of 140 new patents during the reporting period, including 1 domestic invention patent and 40 domestic utility model patents[2]. - Research and development expenses increased to CNY 11,250,003.34 from CNY 9,331,953.01, indicating a focus on innovation and new product development[101]. - The company has not reported any significant research and development expenditures or asset impairment losses during the reporting period[121]. Shareholder Information - The company completed the distribution of 19,459,800 shares as stock dividends and paid cash dividends totaling ¥38,919,600.00 on May 11, 2023[2]. - The total number of ordinary shares increased to 68,109,800 shares after a distribution of 19,459,800 shares during the reporting period[72]. - The largest shareholder, Zhang Wen, holds 38,415,283 shares, representing 56.40% of the total shares[74]. - The company’s public shareholder ratio is currently 25.0031%, which will decrease to 23.97% if the maximum repurchase is completed[61]. Risk Management - The company anticipates risks related to macroeconomic conditions affecting consumer spending and demand for high-quality products[54]. - The company has implemented measures to protect its intellectual property and mitigate risks associated with potential infringements[57]. - The company has not reported any major changes in significant risks during the period, suggesting a stable risk management environment[57]. Operational Efficiency - The company is focused on improving operational efficiency and cost competitiveness through better management practices and market expansion strategies[56]. - The company has established a multi-dimensional sales network covering various regions and international markets, including the US, EU, Japan, and South Korea[26]. Legal and Compliance - There are no significant litigation or arbitration matters reported during the period, indicating a stable legal environment for the company[60]. - The company has no outstanding preferred shares or convertible bonds as of the reporting date[77]. - The company has not experienced any changes in related party relationships or the scope of consolidated financial statements[120].

Financial Performance - Operating revenue for the first quarter of 2023 was ¥65,702,572.60, representing a decline of 20.11% year-on-year[8]. - Net profit attributable to shareholders for the first quarter was ¥1,422,490.77, down 91.14% from the same period last year[8]. - The company reported a total profit of CNY 1,377,634.24 for Q1 2023, significantly lower than CNY 18,424,143.88 in Q1 2022, a decline of 92.5%[125]. - Operating profit for Q1 2023 was CNY 1,309,025.85, compared to CNY 18,295,785.78 in Q1 2022, reflecting a decrease of 92.9%[125]. - Total comprehensive income amounted to CNY 3,978,262.22 for the current period, compared to CNY 17,250,018.16 in the previous period[129]. - Basic earnings per share for Q1 2023 were CNY 0.0292, down from CNY 0.4299 in Q1 2022, a decrease of 93.2%[126]. Cash Flow - The net cash flow from operating activities decreased by 61.89% year-on-year, totaling -¥15,559,290.14[9]. - Cash inflow from operating activities was CNY 86,670,913.40, a decrease from CNY 92,191,393.12 year-over-year[130]. - Net cash flow from operating activities was negative CNY 15,559,290.14, compared to negative CNY 9,610,964.13 in the same period last year[130]. - Cash inflow from investment activities totaled CNY 252,305,014.07, significantly up from CNY 29,380,038.36 in the previous year[131]. - Net cash flow from investment activities was negative CNY 5,064,813.29, compared to negative CNY 4,060,527.64 in the prior year[131]. - Cash inflow from financing activities was CNY 10,000,000.00, unchanged from the previous year[131]. - Net cash flow from financing activities was negative CNY 1,805,363.98, a decline from positive CNY 7,703,528.40 in the same period last year[131]. - The ending balance of cash and cash equivalents was CNY 48,413,103.59, down from CNY 24,805,373.18 year-over-year[131]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥599,333,840.57, a decrease of 2.04% compared to the previous year-end[8]. - The total current assets were ¥536,240,900.18, down from ¥552,691,028.72, indicating a decrease of about 3.0%[116]. - Total liabilities decreased to ¥79,702,693.32 from ¥93,872,251.73, a decline of about 15.0%[118]. - The company's total liabilities decreased to CNY 69,729,956.07 in Q1 2023 from CNY 85,559,047.44 in Q1 2022, a reduction of 18.5%[122]. - The total equity attributable to shareholders increased slightly by 0.32% to ¥519,631,147.25 compared to the previous year-end[8]. - The total equity increased to CNY 520,283,138.03 in Q1 2023 from CNY 516,052,284.17 in Q1 2022, showing a slight increase of 0.4%[122]. Share Repurchase and Governance - The company plans to repurchase shares with a total amount estimated between 9.54 million and 15.96 million RMB, representing 0.62%-1.03% of the total share capital[30]. - The maximum repurchase price is set at 31.80 RMB per share, based on the average trading price of 26.84 RMB over the previous 24 trading days[30]. - The repurchase plan is aimed at enhancing the company's governance structure and long-term incentive mechanisms[29]. - The repurchase implementation period is set for up to three months from the approval date by the shareholders' meeting[31]. - The company will adjust the repurchase price if there are any equity distributions during the repurchase period[30]. - The repurchase will not lead to a situation where the company fails to meet the listing conditions of the Beijing Stock Exchange[31]. Commitments and Compliance - The company is currently fulfilling its commitment regarding the issuance of shares with a lock-up promise initiated on May 27, 2022[35]. - The company has ongoing commitments related to profit distribution, initiated on May 27, 2022, ensuring compliance with the outlined details[35]. - The company is actively addressing measures to stabilize stock prices as part of its commitments made on August 24, 2022[35]. - The company guarantees that the submitted issuance application documents do not contain false records, misleading statements, or major omissions[87]. - If there are false records or major omissions in the prospectus, the company will repurchase all newly issued shares at the issuance price plus bank interest[87]. - The company will announce any failure to fulfill commitments on the next trading day after confirmation of the failure[91]. Related Party Transactions - The company has confirmed that there are no other significant related party transactions during the reporting period[27]. - The controlling shareholders and actual controllers of the company have committed to strictly fulfill their public commitments and accept social supervision[96]. - The controlling shareholders will reduce and regulate related party transactions, ensuring compliance with relevant laws and fair market pricing[104]. - The company will not provide funds to the controlling shareholders or their controlled enterprises without a legitimate transaction background[108].

证券代码：870199 证券简称：倍益康 公告编号：2023-044 四川千里倍益康医疗科技股份有限公司 2022 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、说明会类型 四川千里倍益康医疗科技股份有限公司（以下简称"公司"）于 2023 年 4 月 7 日在北京证券交易所官方信息披露平台（http://www.bse.cn）发布了《2022 年年 度报告》（公告编号：2023-028），为方便广大投资者更深入了解公司 2022 年年 度经营业绩的具体情况，公司拟召开 2022 年年度报告业绩说明会。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 4 月 20 日 15:00-17:00。 公司董事长、总经理：张文 先生 公司董事会秘书、副总经理：蔡秋菊 女士 公司财务负责人：温莉 女士 公司保荐代表人：韩琰 先生 四、投资者参加方式 本次说明会采用网络方式召开。 投资者可登录上海证券报官网"路演中心"（https://roadshow.cnstoc ...

Intellectual Property and Innovation - In 2022, the company added 226 patents, including 6 invention patents, 76 utility model patents, and 144 design patents[7]. - The number of patents owned by the company increased to 522, up from 298 in the previous period, including 19 invention patents[93]. - The company is focusing on enhancing its independent research and development capabilities to optimize product performance and production processes[105]. Financial Performance - The company's revenue for 2022 was CNY 391,067,881.41, representing an 18.84% increase compared to CNY 329,063,034.64 in 2021[31]. - The net profit attributable to shareholders for 2022 was CNY 70,017,821.64, a decrease of 12.27% from CNY 79,810,344.85 in 2021[31]. - The company's gross profit margin for 2022 was 38.79%, down from 41.82% in 2021[31]. - The weighted average return on equity for 2022 was 37.41%, a decrease from 93.99% in 2021[31]. - The cash flow from operating activities for 2022 was CNY 39,738,742.43, a decline of 30.87% compared to CNY 57,483,225.98 in 2021[34]. - The company reported a net profit margin of 17.91% for 2022, compared to 24.24% in 2021[31]. Market and Product Development - The revenue from the muscle massager, a key product, amounted to 346.7947 million RMB, accounting for 89.72% of the main business income[15]. - The self-owned brand "beoka" contributed 30.01% to the main business income, indicating significant growth potential[15]. - The company is focused on developing intelligent rehabilitation equipment, with a reliance on physical factor series products[15]. - The company is expanding its product line with the introduction of new portable oxygen machines and massage systems, aiming to enhance market sales and meet customer demands[95]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth[28]. Customer Concentration and Risks - The top five customers accounted for 64.15% of the total revenue, highlighting a relatively high customer concentration risk[15]. - The company faces risks related to market demand fluctuations and competition in the healthcare sector[14]. - The company acknowledges risks related to fluctuations in downstream market demand and increasing promotional costs on e-commerce platforms[107]. Investments and Assets - The total assets at the end of 2022 reached CNY 611,828,316.57, a significant increase of 183.57% from CNY 215,761,768.87 at the end of 2021[33]. - Cash and cash equivalents increased by 42.62 million, a growth of 138.50%, primarily due to increased operational receipts and funds raised from a public stock offering[52]. - Trading financial assets grew by 287.16 million, a significant increase of 595.13%, as the company invested idle funds in structured deposits[53]. Shareholder and Corporate Governance - The company is currently fulfilling its commitment regarding share lock-up and profit distribution as of May 27, 2022[124]. - The company has established strict penalties for shareholders who violate their commitments, including public apologies and compensation for investor losses[143]. - The company commits to distributing profits to shareholders according to the approved profit distribution policy, ensuring compliance with the procedures outlined in the articles of association[144]. Research and Development - R&D expenses rose by 6.74 million yuan, a growth of 45.74%, driven by enhanced investment in new medical product development[60]. - R&D expenditure increased to CNY 21.47 million, accounting for 5.49% of total operating revenue, up from 4.48% in the previous period[90]. - The company is collaborating with Sichuan University West China Hospital on the development of a wearable osteoporosis magnetic therapy device[96]. Compliance and Legal Matters - The company has not encountered any significant uncertainties affecting its future business strategy or plans during the reporting period[106]. - The company has not reported any significant litigation or arbitration matters during the reporting period[120]. - The company has committed to ensuring that the issuance application documents do not contain false records or misleading statements[163].